R.J. Corman Railroad Group

CARsgen Announces Formation of its Clinical Advisory Board

Retrieved on: 
星期一, 十一月 20, 2023
Dexamethasone, Experiment, Teaching hospital, Patient, Strategic planning, Bortezomib, Vall d'Hebron University Hospital, Cancer, Ernest Beutler, TCO, Doctor of Philosophy, Knowledge, Axicabtagene ciloleucel, University of Miami, Multiple myeloma, Douglas E. Lynch, R.J. Corman Railroad Group, University, ESMO, Harvard Medical School, Regorafenib, Biomarker, Principal, Translation, Vall, MD Anderson Cancer Center, Lenalidomide, Therapy, National Cancer Institute, Dana–Farber Cancer Institute, MGUS, Publication, Drug development, NCI-designated Cancer Center, The Lancet, Research, Lymphoid leukemia, NCI, CD19, MRD, FDA, MD, Survival, Lymphoma, Pharmaceutical industry, Daratumumab, Medicine, Immunotherapy

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.

Key Points: 
  • SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.
  • This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.
  • "As we embark on this exciting journey to advance our differentiated CAR T-cell therapies, I am delighted to welcome our esteemed Clinical Advisory Board members.
  • The formation of this Clinical Advisory Board marks a significant step forward for CARsgen as it continues to pioneer CAR T-cell therapies with the potential to transform cancer treatment.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
星期一, 十二月 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

Retrieved on: 
星期一, 十二月 12, 2022
R.J. Corman Railroad Group, Oncology, Hematology, Serum, CBP, Internal medicine, PR, Multiple myeloma, Drug discovery, Society, Endpoint security, Mayo Clinic College of Medicine and Science, Patient, DNA, Mayo Clinic, University of Cambridge, Cancer, Dana–Farber Cancer Institute, Oncogene, Research, Gurdon Institute, Partial-response maximum-likelihood, Takeda Pharmaceutical Company, Division, Disease, NHS foundation trust, MCRPC, Dexamethasone, RRMM, MYC, The Christie NHS Foundation Trust, Lymphatic system, Translation, University, IRF4, University of Manchester, Harvard Medical School, Gene, Toxic leukoencephalopathy, ASH, Cancer research, Medical imaging, Pharmaceutical industry, Medicine

Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."

Key Points: 
  • Taken together, these findings provide clear encouragement for the further clinical development of this first in class drug."
  • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
    CellCentric has developed inobrodib from concept through to clinical trials.
  • It is an oral, first in class small molecule inhibitor drug that targets twin cancer gene regulators p300 and CBP.
  • The company actively pursued multiple drug discovery programmes before prioritising p300/CBP inhibition and inobrodib.

Paula and Rodger Riney Foundation Makes $40 Million Transformative Grant to Further Multiple Myeloma Research at Dana-Farber Cancer Institute

Retrieved on: 
星期四, 一月 6, 2022
Oncology, Philanthropy, Health, Foundation, Clinical Trials, Research, Science, Family, Harvard Medical School, Therapy, COVID-19, Richard, Health, News, NCI-designated Cancer Center, Research, Education, Patient, Hospital, Adult, Organization, Multiple myeloma, Dana–Farber Cancer Institute, Cancer, Institute, CEO, Anderson, Partnership, Cohesion, CAR, Multimedia, R.J. Corman Railroad Group, Leadership, Pharmaceutical industry, Vaccine, Dietary supplement, MD, Medicine

Paula and Rodger Riney of St. Louis, MO, through the Paula and Rodger Riney Foundation, have announced a $40 million grant to support multiple myeloma research at Dana-Farber Cancer Institute .

Key Points: 
  • Paula and Rodger Riney of St. Louis, MO, through the Paula and Rodger Riney Foundation, have announced a $40 million grant to support multiple myeloma research at Dana-Farber Cancer Institute .
  • The Paula and Rodger Riney Foundation has been a strong supporter of Dana-Farber and with this grant has cumulatively donated nearly $60 million to the Institute.
  • View the full release here: https://www.businesswire.com/news/home/20220106005068/en/
    Paula and Rodger Riney of St. Louis, MO, through the Paula and Rodger Riney Foundation, have announced a $40 million grant to support multiple myeloma research at Dana-Farber Cancer Institute.
  • I extend my heartfelt thanks to Paula and Rodger Riney for their unprecedented support of our research to develop novel treatments for multiple myeloma.